EP. 1: Dr. Graff on Initial Steps for Treating Metastatic HR-Positive Breast Cancer
Stephanie L. Graff, MD, discusses the initial steps for treating patients with metastatic hormone receptor–positive breast cancer.
EP. 2: Dr. O’Regan on the Development of Oral SERDs in Breast Cancer
Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.
EP. 3: Dr. Litton on Remaining Questions in ESR1-Mutated Breast Cancer
Jennifer Keating Litton, MD, discusses research areas of interest in ESR1-mutated, endocrine receptor–positive, HER2-negative breast cancer.
EP. 4: Exploring Recent Developments in the Treatment of Patients With Hormone Receptor– Positive Breast Cancer
A select group oncology experts met to engage in a virtual discussion workshop moderated by oncologist Erika Hamilton, MD. The overall objectives were to review recent data on therapeutic advances in HR+ BC. This article summarizes data from recent trials in early HR+ and TNBC; HR+ metastatic BC, focusing on use of CDK4/6 inhibitors in the first line and second line and beyond; and promising new endocrine therapies that may represent the future direction of HR+ cancer treatment.
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC
Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer
